艾伯维
ABBV222.000USD
+1.190+0.54%
收盘 09/18, 16:00（美东）报价延迟15分钟
392.15B总市值
105.33市盈率 TTM
关于 艾伯维 公司
艾伯维为一家多元、科研驱动的生物制药领跑者，专注药物与疗法的研发、生产、商业化与销售。公司透过遍布美洲、欧洲与亚洲的生产与行销渠道，将疗法推向逾一百七十五个市场 。产品线横跨免疫学、肿瘤学、医美、神经科学、眼科护理及其他专科。免疫学覆盖风湿、皮肤与肠胃疾病；肿瘤学聚焦急性髓系、急性淋系、慢性淋系白血病及弥漫性大B细胞淋巴瘤；神经领域涵括帕金森、偏头痛、运动与精神障碍及阿兹海默；眼科护理面向慢性干眼、青光眼、老年性视网膜退化与屈光不正；医美业务提供 Botox Cosmetic、The Juvederm Collection of Fillers 等注射产品。管线中 NX-13 用于溃疡性结肠炎与克隆氏病治疗；CEL383 锁定炎症性肠病；ALIA-1758 瞄准阿兹海默患者群体。
公司简介
公司代码ABBV
公司名称AbbVie Inc
上市日期Jan 02, 2013
CEOMr. Robert A. Michael, CPA
员工数量55000
证券类型Ordinary Share
年结日Jan 02
公司地址1 N Waukegan Rd
城市NORTH CHICAGO
上市交易所NYSE Consolidated
国家United States of America
邮编60064
电话18479327900
网址https://www.abbvie.com/
公司代码ABBV
上市日期Jan 02, 2013
CEOMr. Robert A. Michael, CPA
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.33%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.87%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-77.61%
Ms. Jennifer L. Davis
Ms. Jennifer L. Davis
Independent Director
Independent Director
2.52K
+91.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Immunology-SKYRIZI
3.42B
25.21%
Immunology-RINVOQ
1.72B
12.64%
Immunology-HUMIRA
1.12B
8.25%
Hematologic Oncology-IMBRUVICA
947.00M
6.97%
Neuroscience-Botox Therapeutic
866.00M
6.37%
其他
5.51B
40.56%
地区USD
名称
营收
占比
United States
9.39B
69.13%
International
3.20B
23.56%
All other countries
747.00M
5.50%
Collaboration revenue
245.00M
1.80%
业务
地区
业务USD
名称
营收
占比
Immunology-SKYRIZI
3.42B
25.21%
Immunology-RINVOQ
1.72B
12.64%
Immunology-HUMIRA
1.12B
8.25%
Hematologic Oncology-IMBRUVICA
947.00M
6.97%
Neuroscience-Botox Therapeutic
866.00M
6.37%
其他
5.51B
40.56%
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.99%
BlackRock Institutional Trust Company, N.A.
5.21%
State Street Global Advisors (US)
4.53%
Geode Capital Management, L.L.C.
2.22%
JP Morgan Asset Management
2.12%
其他
75.93%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.99%
BlackRock Institutional Trust Company, N.A.
5.21%
State Street Global Advisors (US)
4.53%
Geode Capital Management, L.L.C.
2.22%
JP Morgan Asset Management
2.12%
其他
75.93%
股东类型
持股股东
占比
Investment Advisor
43.57%
Investment Advisor/Hedge Fund
19.92%
Research Firm
3.07%
Bank and Trust
2.29%
Pension Fund
2.19%
Sovereign Wealth Fund
1.40%
Hedge Fund
1.28%
Insurance Company
0.68%
Family Office
0.20%
其他
25.39%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
5271
1.32B
74.93%
+10.38M
2025Q1
5332
1.32B
74.90%
+11.71M
2024Q4
5219
1.31B
74.47%
+8.91M
2024Q3
4974
1.30B
73.54%
-7.44M
2024Q2
4916
1.30B
73.53%
+2.27M
2024Q1
4930
1.29B
72.58%
-1.47M
2023Q4
4882
1.28B
72.31%
-1.48M
2023Q3
4694
1.27B
71.87%
-12.06M
2023Q2
4688
1.26B
71.51%
-30.42M
2023Q1
4658
1.27B
71.97%
-18.58M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
177.27M
10.04%
+4.12M
+2.38%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
91.03M
5.15%
+950.86K
+1.06%
Mar 31, 2025
State Street Global Advisors (US)
79.96M
4.53%
+341.48K
+0.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
38.25M
2.17%
+1.11M
+2.98%
Mar 31, 2025
JP Morgan Asset Management
35.61M
2.02%
+1.70M
+5.02%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
25.27M
1.43%
-2.17M
-7.91%
Mar 31, 2025
Capital Research Global Investors
33.51M
1.9%
-475.69K
-1.40%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
23.25M
1.32%
+571.37K
+2.52%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
25.10M
1.42%
+2.62M
+11.64%
Dec 31, 2024
Fidelity Management & Research Company LLC
21.43M
1.21%
+4.44M
+26.15%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Direxion Daily Healthcare Bull 3X Shares
5.47%
Bahl & Gaynor Dividend ETF
2.85%
Capital Group Conservative Equity ETF
1.81%
PIMCO RAFI ESG US ETF
1.67%
Franklin US Large Cap Multifactor Index ETF (US)
1.63%
ALPS O'Shares US Quality Dividend ETF
1.1%
Stance Sustainable Beta ETF
1.04%
iShares Climate Conscious & Transtn MSCI USA ETF
0.91%
Franklin US Equity Index ETF
0.69%
Columbia Research Enhanced Core ETF
0.69%
查看更多
Direxion Daily Healthcare Bull 3X Shares
占比5.47%
Bahl & Gaynor Dividend ETF
占比2.85%
Capital Group Conservative Equity ETF
占比1.81%
PIMCO RAFI ESG US ETF
占比1.67%
Franklin US Large Cap Multifactor Index ETF (US)
占比1.63%
ALPS O'Shares US Quality Dividend ETF
占比1.1%
Stance Sustainable Beta ETF
占比1.04%
iShares Climate Conscious & Transtn MSCI USA ETF
占比0.91%
Franklin US Equity Index ETF
占比0.69%
Columbia Research Enhanced Core ETF
占比0.69%
分红派息
近5年累计派现
48.58B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
Sep 11, 2023
ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 22, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 16, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Oct 28, 2022
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 09, 2022
ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
